Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 1/2018

01-01-2018

LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma

Authors: Kathryn J. Fowler, Theodora A. Potretzke, Thomas A. Hope, Eduardo A. Costa, Stephanie R. Wilson

Published in: Abdominal Radiology | Issue 1/2018

Login to get access

Abstract

LI-RADS v2017 introduces major changes to the diagnostic criteria for LR-M observations to better guide radiologists in the use of this malignant category designation. LR-M is intended to preserve the specificity of the LI-RADS algorithm for diagnosis of HCC while not losing sensitivity for diagnosis of malignancy. The purpose of this paper is to provide a brief background on LR-M, discuss the diagnostic criteria new to v2017, special considerations for its application, and management implications.
Literature
1.
Siegel R, et al. (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30
2.
3.
Ercolani G, et al. (2010) Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 252(1):107–114CrossRefPubMed
4.
5.
Shaib YH, et al. (2005) Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128(3):620–626CrossRefPubMed
6.
Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7(3):462–503CrossRefPubMed
7.
Goodman ZD, et al. (1985) Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 55(1):124–135CrossRefPubMed
8.
Jarnagin WR, et al. (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94(7):2040–2046CrossRefPubMed
9.
Ng IO, et al. (1998) Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol 13(1):34–40CrossRefPubMed
10.
Choi SH, et al. (2016) Liver imaging reporting and data system v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Invest Radiol 51(8):483–490CrossRefPubMed
11.
Chen N, et al. (2016) Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma. Magn Reson Med Sci 15(1):49–59CrossRefPubMed
12.
Darnell A, et al. (2015) Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology 275(3):698–707CrossRefPubMed
13.
Fowler KJ, et al. (2013) Validation of organ procurement and transplant network (OPTN)/united network for organ sharing (UNOS) criteria for imaging diagnosis of hepatocellular carcinoma. Transplantation 95(12):1506–1511CrossRefPubMed
14.
Wald C, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266(2):376–382CrossRefPubMed
15.
16.
Park MJ, et al. (2013) Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma. J Comput Assist Tomogr 37(6):872–881CrossRefPubMed
17.
Chong YS, et al. (2012) Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 67(8):766–773CrossRefPubMed
18.
Kim R, et al. (2016) Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. Eur Radiol 26(6):1808–1817CrossRefPubMed
19.
Rimola J, et al. (2009) Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50(3):791–798CrossRefPubMed
20.
Asayama Y, et al. (2015) Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI. Diagn Interv Radiol 21(2):96–104CrossRefPubMedPubMedCentral
21.
Joo I, et al. (2016) Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging 44(5):1330–1338CrossRefPubMed
22.
Huang B, et al. (2016) Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging. Radiology 281(1):150–157CrossRefPubMed
23.
Park HJ, et al. (2016) Identification of imaging predictors discriminating different primary liver tumours in patients with chronic liver disease on gadoxetic acid-enhanced MRI: a classification tree analysis. Eur Radiol 26(9):3102–3111CrossRefPubMed
24.
Hwang J, et al. (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36(4):881–889CrossRefPubMed
25.
Peporte AR, et al. (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 82(3):e101–e106CrossRefPubMed
26.
Kang Y, et al. (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264(3):751–760CrossRefPubMed
27.
Tsunematsu S, et al. (2015) Intratumoral artery on contrast-enhanced computed tomography imaging: differentiating intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma. Abdom Imaging 40(6):1492–1499CrossRefPubMed
28.
Ciresa M, et al. (2015) Enhancement patterns of intrahepatic mass-forming cholangiocarcinoma at multiphasic computed tomography and magnetic resonance imaging and correlation with clinicopathologic features. Eur Rev Med Pharmacol Sci 19(15):2786–2797PubMed
29.
Potretzke TA, et al. (2016) Imaging features of biphenotypic primary liver carcinoma (Hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 207(1):25–31CrossRefPubMed
30.
Fowler KJ, et al. (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201(2):332–339CrossRefPubMed
31.
Fukukura Y, et al. (1997) Combined hepatocellular and cholangiocarcinoma: correlation between CT findings and clinicopathological features. J Comput Assist Tomogr 21(1):52–58CrossRefPubMed
32.
Sanada Y, et al. (2005) A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol Res 32(3):185–195CrossRefPubMed
33.
Wells ML, et al. (2015) Biphenotypic hepatic tumors: imaging findings and review of literature. Abdom Imaging 40(7):2293–2305CrossRefPubMed
34.
Alustiza JM, et al. (2007) Iron overload in the liver diagnostic and quantification. Eur J Radiol 61(3):499–506CrossRefPubMed
35.
Yuan MX, et al. (2016) Factors affecting the enhancement patterns of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) and their pathological correlations in patients with a single lesion. Ultraschall Med 37(6):609–618PubMed
36.
Kong WT, et al. (2014) Value of wash-in and wash-out time in the diagnosis between hepatocellular carcinoma and other hepatic nodules with similar vascular pattern on contrast-enhanced ultrasound. J Gastroenterol Hepatol 29(3):576–580CrossRefPubMed
37.
Wildner D, et al. (2014) Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. Ultraschall Med 35(6):522–527CrossRefPubMed
Metadata
Title
LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma
Authors
Kathryn J. Fowler
Theodora A. Potretzke
Thomas A. Hope
Eduardo A. Costa
Stephanie R. Wilson
Publication date
01-01-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 1/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1196-2

Other articles of this Issue 1/2018

Abdominal Radiology 1/2018 Go to the issue

OriginalPaper

LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents

Letter to the Editor

Letter to the editor

Invited article

The LI-RADS adventure—a personal statement

OriginalPaper

LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound

Invited article

Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm

Review Paper

LI-RADS: a glimpse into the future
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits